| Articolul precedent |
| Articolul urmator |
 |
 391 1 |
| Ultima descărcare din IBN: 2021-11-28 09:52 |
 SM ISO690:2012SECRIERU, Iulian, TURCAN, Svetlana, GUTULEAC, Elena, POPCOVA, Olga. Concept of informational tool for MAFLD and COVID-19 severity interplay assessment. In: Mathematics and Information Technologies: Research and Education, Ed. 2021, 1-3 iulie 2021, Chişinău. Chișinău, Republica Moldova: 2021, pp. 113-114. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Mathematics and Information Technologies: Research and Education 2021 | ||||||
|
Conferința "Mathematics and Information Technologies: Research and Education" 2021, Chişinău, Moldova, 1-3 iulie 2021 | ||||||
|
||||||
| Pag. 113-114 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
The earliest evidence suggested that obese patients, who often present Metabolic Associated Fatty Liver Disease (MAFLD), are even more vulnerable at severe presentation of COVID-19. On the one hand, the e®ect of compromised liver function, as a result of MAFLD, on the severity of COVID-19 illness [1] has not been well studied yet. We aim to systematize the info and data of patients with fatty liver and evaluate the severity of COVID-19 in this cohort. On the other hand, most likely, these patients will receive drugs necessary for the treatment of acute respiratory syndrome, antiviral agents and other drugs to treat systemic in°ammation, combat bacterial and fungal superinfections. Among these pharmaceuticals can produce some drug-induced liver injury (DILI) [2]. The mechanisms of DILI are not always understood. There is a clear need for a deeper understanding of interplay between MAFLD and severity of COVID-19. For more reliable and accurate results, we plan to create a partnership and combine the e®orts of medical experts and the specialists in the ¯eld of medical informatics. The overall research objective is to elucidate relationship between fatty liver and COVID-19 by creating a data warehouse of MAFLD cases, based on a single ontology (protocol), and to provide intelligent information tool for quantifying and assessing the reciprocation of compromised liver function as a result of MAFLD and the severity of COVID-19 illness, and vice versa, COVID19 treatment and MAFLD progression, using our existing experience [3]. Relevance of the assumed overall objective is enormous, as we have witnessed the wide spread of MAFLD, which predominantly a®ect people of working age, having a signi¯cant negative impact on social and economic development. COVID-19 pandemic only made things worse. The research for this paper have been supported by the COST Action CA17112 \Prospective European Drug-Induced Liver Injury Network" and the project 20.80009.5007.22 \Intelligent information systems for solving ill-structured problems, processing knowledge and big data" in the framework of the State Program. |
||||||
|
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Secrieru, I.P.</dc:creator> <dc:creator>Ţurcan, S.I.</dc:creator> <dc:creator>Guţuleac, E.N.</dc:creator> <dc:creator>Popcova, O.V.</dc:creator> <dc:date>2021</dc:date> <dc:description xml:lang='en'><p>The earliest evidence suggested that obese patients, who often present Metabolic Associated Fatty Liver Disease (MAFLD), are even more vulnerable at severe presentation of COVID-19. On the one hand, the e®ect of compromised liver function, as a result of MAFLD, on the severity of COVID-19 illness [1] has not been well studied yet. We aim to systematize the info and data of patients with fatty liver and evaluate the severity of COVID-19 in this cohort. On the other hand, most likely, these patients will receive drugs necessary for the treatment of acute respiratory syndrome, antiviral agents and other drugs to treat systemic in°ammation, combat bacterial and fungal superinfections. Among these pharmaceuticals can produce some drug-induced liver injury (DILI) [2]. The mechanisms of DILI are not always understood. There is a clear need for a deeper understanding of interplay between MAFLD and severity of COVID-19. For more reliable and accurate results, we plan to create a partnership and combine the e®orts of medical experts and the specialists in the ¯eld of medical informatics. The overall research objective is to elucidate relationship between fatty liver and COVID-19 by creating a data warehouse of MAFLD cases, based on a single ontology (protocol), and to provide intelligent information tool for quantifying and assessing the reciprocation of compromised liver function as a result of MAFLD and the severity of COVID-19 illness, and vice versa, COVID19 treatment and MAFLD progression, using our existing experience [3]. Relevance of the assumed overall objective is enormous, as we have witnessed the wide spread of MAFLD, which predominantly a®ect people of working age, having a signi¯cant negative impact on social and economic development. COVID-19 pandemic only made things worse. The research for this paper have been supported by the COST Action CA17112 \Prospective European Drug-Induced Liver Injury Network" and the project 20.80009.5007.22 \Intelligent information systems for solving ill-structured problems, processing knowledge and big data" in the framework of the State Program.</p></dc:description> <dc:source>Mathematics and Information Technologies: Research and Education () 113-114</dc:source> <dc:title>Concept of informational tool for MAFLD and COVID-19 severity interplay assessment</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>
|
|
|
